Show simple item record

dc.contributor.authorCurley, Clive J.
dc.contributor.authorDolan, Eimear B.
dc.contributor.authorOtten, Matthias
dc.contributor.authorHinderer, Svenja
dc.contributor.authorDuffy, Garry P.
dc.contributor.authorMurphy, Bruce P.
dc.identifier.citationCurley, Clive J., Dolan, Eimear B., Otten, Matthias, Hinderer, Svenja, Duffy, Garry P., & Murphy, Bruce P. (2019). An injectable alginate/extra cellular matrix (ECM) hydrogel towards acellular treatment of heart failure. Drug Delivery and Translational Research, 9(1), 1-13. doi: 10.1007/s13346-018-00601-2en_IE
dc.description.abstractAs treatments for myocardial infarction (MI) continue to improve, the population of people suffering from heart failure (HF) is rising significantly. Novel treatment strategies aimed at achieving long-term functional stabilisation and improvement in heart function post MI include the delivery of biomaterial hydrogels and myocardial matrix-based therapies to the left ventricle wall. Individually alginate hydrogels and myocardial matrix-based therapies are at the most advanced stages of commercial/clinical development for this potential treatment option. However, despite these individual successes, the potential synergistic effect gained by combining the two therapies remains unexplored. This study serves as a translational step in evaluating the minimally invasive delivery of dual acting alginate-based hydrogels to the heart. We have successfully developed new production methods for hybrid alginate/extracellular matrix (ECM) hydrogels. We have identified that the high G block alginate/ECM hybrid hydrogel has appropriate rheological and mechanical properties (1.6 KPa storage modulus, 29 KPa compressive modulus and 14 KPa dynamic modulus at day 1) and can be delivered using a minimally invasive delivery device. Furthermore, we have determined that these novel hydrogels are not cytotoxic and are capable of enhancing the metabolic activity of dermal fibroblasts in vitro (p < 0.01). Overall these results suggest that an effective minimally invasive HF treatment option could be achieved by combining alginate and ECM particles.en_IE
dc.description.sponsorshipAMCARE project funded by European Union’s ‘Seventh Framework’ Programme for research, technological development and demonstration under Grant Agreement no. NMP3-SME-2013-604531.en_IE
dc.publisherSpringer Verlagen_IE
dc.relation.ispartofDrug Delivery And Translational Researchen
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 Ireland
dc.subjectHeart failureen_IE
dc.subjectAcellular hydrogelen_IE
dc.subjectMinimally invasive delivery catheteren_IE
dc.titleAn injectable alginate/extra cellular matrix (ECM) hydrogel towards acellular treatment of heart failureen_IE
dc.contributor.funderSeventh Framework Programmeen_IE
dc.local.contactEimear Dolan, Biomedical Engineering 3031, College Of Engineering & Informa, Nui Galway. Email:
dcterms.projectinfo:eu-repo/grantAgreement/EC/FP7::SP1::NMP/604531/EU/Advanced Materials for Cardiac Regeneration (AMCARE)/AMCAREen_IE

Files in this item


This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivs 3.0 Ireland
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 Ireland